版本:
中国

BRIEF-Tesaro to expand development program for Niraparib drug

March 27 Tesaro Inc

* Tesaro announces expanded development program for Niraparib focused on the treatment of front-line metastatic ovarian and lung cancers and metastatic breast cancer

* Tesaro - also expect to initiate new trial of Niraparib in combination with anti-pd-1 antibody in women with metastatic triple-negative breast cancer Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐